文献速递甲状腺与颈部外科围术期管理与 ERAS

甲状旁腺切除术与原发性甲状旁腺功能亢进患者高血压的关联

Parathyroidectomy for Patients With Primary Hyperparathyroidism and Associations With Hypertension.
PubMed 文献 · JAMA Surg · 2020-01-01

这项队列研究纳入2380例原发性甲状旁腺功能亢进合并高血压患者,比较接受与未接受甲状旁腺切除术者的平均动脉压和降压药使用。结果显示手术组平均动脉压改善更明显,且需要增加降压药的风险更低,基线未用药者术后启动降压治疗的比例也更低。

要点

  • 甲状旁腺切除术与平均动脉压改善及降压药需求减少独立相关。
  • 基线未用降压药者,手术组术后启动降压治疗比例更低。
  • 合并高血压尤其是未用药者,在权衡手术时应予考虑。

核心结论

  • 在原发性甲状旁腺功能亢进合并高血压患者中,甲状旁腺切除术可能与平均动脉压更大幅度下降及降压药需求减少相关。
  • 甲状旁腺切除术减少了开始服用降压药的患者人数。
  • 尚需进一步研究明确甲状旁腺切除术是否带来下游心血管获益。

研究设计与样本

  • 队列研究及回顾性数据库review,纳入2008年1月1日至2016年12月31日期间的原发性甲状旁腺功能亢进合并高血压患者。
  • 共2380例参与者,女性占79.0%,其中接受甲状旁腺切除术者501例,未手术者1879例。
  • 比较两组在6个月、1年、2年时的平均动脉压及降压药使用数量,并采用多变量logistic回归评估调整比值比。

主要发现

  • 手术组较未手术组更年轻(平均年龄65.3岁 vs 71.9岁,P < .001),基线降压药数量更少(平均1.2 vs 1.5,P < .001)。
  • 基线至1年平均动脉压变化:未手术组0.1 mm Hg,手术组-1.2 mm Hg(P = .002)。
  • 未手术组较手术组在6个月(15.9% vs 9.8%,P = .001)、1年(18.1% vs 10.8%,P < .001)、2年(17.6% vs 12.2%,P = .004)更可能需要增加降压药。
  • 多变量分析显示甲状旁腺切除术与各时段免于增加降压药独立相关(如1年调整OR 0.49,95%CI 0.34-0.70,P < .001)。
  • 基线未用降压药者中,手术组较未手术组在各时段启动降压治疗比例更低(如1年10.2% vs 30.4%,P < .001)。

临床怎么用

  • 对原发性甲状旁腺功能亢进合并高血压患者,尤其是尚未服用降压药者,在决定手术时应将高血压状态纳入考量。
  • 甲状旁腺切除术可能有助于改善血压控制并减少降压药升级需求。

局限性

  • 原文未明确报告研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hyperparathyroidism is associated with cardiovascular disease. However, evidence for a beneficial consequence of parathyroidectomy on hypertension is limited. OBJECTIVE: To investigate if parathyroidectomy improves hypertension in patients with primary hyperparathyroidism (PHPT). DESIGN, SETTING, AND PARTICIPANTS: In this cohort study and retrospective database review, patients with PHPT and hypertension between January 1, 2008, and December 31, 2016, were identified. The mean arterial pressure (MAP) and number of antihypertensive medications were compared between those who did and did not undergo parathyroidectomy. The setting was a large health care system. Primary hyperparathyroidism was defined using biochemical data, and hypertension was identified by International Classification of Diseases, Ninth Revision codes. EXPOSURE: Parathyroidectomy was identified in the database by Current Procedural Terminology codes. MAIN OUTCOMES AND MEASURES: The MAP and use of antihypertensive medications were compared for patients who underwent parathyroidectomy and those who did not at 6 months, 1 year, and 2 years. Multivariable logistic regression was used to assess the adjusted odds ratios for both increased and decreased use of antihypertensive medications. RESULTS: In this cohort study of 2380 participants (79.0% female), patients undergoing parathyroidectomy (n = 501) were younger (mean [SD] age, 65.3 [9.7] vs 71.9 [10.4] years; P < .001) and took fewer antihypertensive medications at baseline (mean [SD] number of medications, 1.2 [1.1] vs 1.5 [1.3], P < .001) than nonsurgical patients (n = 1879). Patients with parathyroidectomy showed greater improvement in their MAP at all follow-up time points (the median [SD] MAP change from baseline to 1 year was 0.1 [8.7] mm Hg without parathyroidectomy vs -1.2 [7.7] mm Hg after parathyroidectomy, P = .002). Nonsurgical patients were more likely vs those with parathyroidectomy to require more antihypertensive medications at 6 months (15.9% [n = 298] vs 9.8% [n = 49], P = .001), 1 year (18.1% [n = 340] vs 10.8% [n = 54], P < .001), and 2 years (17.6% [n = 330] vs 12.2% [n = 61], P = .004). By multivariable analysis, parathyroidectomy was independently associated with freedom from an increased number of antihypertensive medications at all periods (eg, adjusted odds ratio, 0.49; 95% CI, 0.34-0.70; P < .001 at 1 year). Among patients who were initially not taking antihypertensive medications, patients with parathyroidectomy were less likely vs no surgery to start antihypertensive medication treatment at all periods (eg, 10.2% [13 of 127] vs 30.4% [136 of 447], P < .001 at 1 year). CONCLUSIONS AND RELEVANCE: This study's findings suggest that, among hypertensive patients with PHPT, parathyroidectomy may be associated not only with greater decreases in their MAP but also with reduced requirements for antihypertensive medications. Parathyroidectomy decreased the number of patients who began taking antihypertensive medications. Additional study will be required to find whether there are downstream cardiovascular benefits of parathyroidectomy. Preexisting hypertension, particularly in those not already taking antihypertensive medications, should be considered when weighing surgical treatment.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Graff-Baker AN, Bridges LT, Chen Q, et al. Parathyroidectomy for Patients With Primary Hyperparathyroidism and Associations With Hypertension. JAMA Surg. 2020. PMID: 31596437. doi:10.1001/jamasurg.2019.3950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。